Earnings call
Advanced Enzyme Technologies Q3 FY26 earnings call: Advanced Enzyme Technologies Limited said Nutrazyme would generate a small sale of around INR 1 crore to INR 1.5 crore by the end of the year
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company said Nutrazyme would generate a small sale of around INR 1 crore to INR 1.5 crore by the end of the year. The company said it would undertake capacity expansion when necessary, probably in FY28-29, at a cost of about INR 50 crore. The company said U.S. companies would pass on some cost increases to customers during 2026, while considering whether competitors were also ready to raise prices.
The numbers management gave
Results
- The company said registrations in Asia and other countries had yielded results, with growth in Asia and the rest of the world. Replaced by a later filing.
Show source
The work which we did in the last two, three, fou r years, they are yielding some results right now, and we can see that there is certain growth in the Asia, as well as in the rest of the world area.
What it expects ahead
What management expects
- The company said Nutrazyme would generate a small sale of around INR 1 crore to INR 1.5 crore by the end of the year.
Show source
As of now, with the way we see it, this year it will be a small sale from around INR 1 crore to INR 1.5 crore for the end of the year.
- The company expects overall growth of 13% to 15% on a continuous basis in three to five years.
Show source
We'll grow 13 % to 15% double digit, more than double digit growth overall on a continuous basis in three to five years.
- The company expected the EBITDA impact to be around 1% rather than 2%, after observing the impact for another three months.
Show source
So I think another three months we have to see the impact, but it is most likely instead of 2% on EBITDA, I think it will be around 1% or so.
- The company said it was seeing more inquiries and interest that would reflect in next years. Replaced by a later filing.
Show source
I mean, what we are looking at is a lot more inquiries, lot more interest that will reflect in next years.
What it is building and selling
Projects and capacity
- The company said it would undertake capacity expansion when necessary, probably in FY28-29, at a cost of about INR 50 crore.
Show source
Sorry, FY26-27, FY27-28 -- yeah, FY28-29 mostly and the cost will be about INR 50 crore at that point.
- The company expected the facility to be commissioned around the end of the second quarter of the coming year. Replaced by a later filing.
Show source
Mukund Kabra Somewhere around the end of the second quarter of this coming year.
Demand and pricing
- The company said U.S. companies would pass on some cost increases to customers during 2026, while considering whether competitors were also ready to raise prices.
Show source
So, most of the things if you will see, that U.S. companies will pass on some of the cost increases to the customers during this 2026.
- The company said consumers were being heavily affected by slowing markets in food and pharma, and people were holding back on placing new orders amid marketplace uncertainty.
Show source
And in that particular place, people try to hold on to placing any new orders.
Risks, rules and outside factors
Outside factors
- The company said uncertainty in the U.S. human nutrition market and heavy duties on nutritional products were making short- and long-term strategies difficult to develop.
Show source
Overall, the market is very uncertain in U.S. and when there is a complete uncertainty in nutritional market, everybody is paying a heavy duty no matter where the product is coming from in the nutritional market, human nutrition market.
- The company said costs from China for raw materials, packaging and shipping were going up, and the industry was trying to pass on those costs gradually.
Show source
Second part is the cost, which is coming out from the China on all the raw materials for packaging, shipping, etc. It is going up, and the industry is trying to pass on that cost a little bit at a time.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Umang Shah Okay.
Answer, beni rauka
Beni Rauka India is INR 1,710 million and for the international market, INR 1,686 million. So total is INR 3,396 million for nine months.
Question
Umang Shah Yeah, tell me sir.
Answer, vasant rathi
Vasant Rathi Page 5 of 23 You know what is going on. Overall, the market is very uncertain in U.S. and when there is a complete uncertainty in nutritional market, everybody is paying a heavy duty no matter where the product is coming from in the nutritional market, human nutrition market. And long-term strategies, short-term strategies are difficult to develop during this kind of uncertain markets. Second part is the cost, which is coming out from the China on all the raw materials for packaging, shipping, etc. It is going up, and the industry is trying to pass on that cost a little bit at a time. And you can see that there is a slowing down, not because only on the nutritional side also, but the market-wise, it is affecting the consumers very, very heavily in the food segment, in pharma segment everywhere. So overall, there is a tremendous uncertainty in the marketplace. And in that particular place, people try to hold on to placing any new orders.
Question
Umang Shah Yes. Got it, sir. Very useful. Sir, and second question was what is the competitive intensity in our largest product in India? Is it normalizing compared to last year or is it still quite high?
Answer, mukund kabra
Mukund Kabra Umang Ji, you can see the numbers, and if you see the numbers, slowly we are growing, right? So I don't see there is any problem for competencies or any other area into that particular.
Question
Umang Shah Got it, sir. Got it. Sir, and last question was, at the end of the last year, you had mentioned that we want to have a business in intermediates also. It's been -- I mean, it's been -- nine months of this year has been done. Any headway in this business?
Answer, mukund kabra
Mukund Kabra We are still working on that. And probably when the right time will come, we'll come out of it, okay.
Question
Umang Shah Okay. Got it. Sure, sir.
Answer, vasant rathi
Vasant Rathi But the plan is going well. Hopefully the market conditions will help us establish the foothold.
Question
My questions are not about this quarter or nine months, but slightly medium to long term. And so first one is, how are you monitoring potential disruptive technologies or new entrants in the enzyme space, and what steps are you taking to ensure that once enzyme is not kind of blindsided by them?
Answer, vasant rathi
Vasant Rathi Very, very interesting question, and thank you for asking that. Listen, there is technologies which are coming in or the new entrants coming into the marketplace. There are certain segments in the human nutrition where people are more concerned with, and we are addressing that through our lot of research of new products, new areas. It takes little time to develop these new enzymes per se, because it has to go through lot of regulatory approvals, etc. But we are already, as you will see, that we are very much, very much on top of it publishing our papers . We are also trying to get technical backgrounds and support systems, because people nowadays don't like just an ingredient per se. They want a research data supporting it, and which too also with the peer review papers. And that's how we are trying to attack that market , to make sure that we keep our lead continuously into this market.
Question
Sajal Kapoor Yeah. That's helpful. And yes, I agree it takes time to commercialize the new discovery taking on you know -- it's time consuming. Nothing works over overnight in this industry, so I completely appreciate that. And my second question is, how do you decide when to invest in incremental improvements and to existing products versus pioneering entirely new enzyme solutions that might initially serve only a smaller or a less profitable market, but you know, that may potentially lead into longer term opportunities. So basically, the question is, how do you decide when to sort of become more cost efficient because of competitive pressures or otherwise in your existing products versus w
Answer, vasant rathi
Vasant Rathi Mindset is, basically you go to the marketplace where you have better profit margins to begin with, and then expanding to the markets where there is margin pressure, but the volume gives us a cost competitive advantage into our manufacture because of the volume.
Question
Sajal Kapoor Do you keep separate teams for novel innovation, something which is getting discovered and versus incremental improvements? Or are these the same teams?
Answer, vasant rathi
Vasant Rathi No. The teams, you had to separate them and get most of the efficiencies, cost efficiencies, because nowadays travel is very expensive as you know, okay. Besides, AI is coming into picture, so a lot of people are ‘self-educated’ per se, you know. So, it is always a very interesting market dynamics where people throw the questions from AI, wanted to know all the answers kind of thing. And this is a technical field a little bit, so you have to explain it in the marketplace to make them understand why it is different. It is not the same thing. Page 7 of 23 Sajal Kapoor Yes, sure.
Question
But my question was, is it a single R&D center, because we have got multiple R&D centers. So, how do we position them for new innovation versus improvement? Vasant Rathi: No. There is single, R&D center.
Answer, mukund kabra
Mukund Kabra R&D center is single, but they are subdivided into different departments, functionality wise, okay. So, there are different people taking care of different areas.
Question
Shreyans Gathani Hi, good afternoon. I had just had one question. So, from my understanding, the sales in the Evoxx subsidiary just go to Europe. Would that be the right understanding?
Answer, vasant rathi
Vasant Rathi Yes, it the right understanding.
Show 20 more questions
Question
Shreyans Gathani Okay. So, based on that, so if I look at excluding the Evoxx, pretty much our sales have dropped. I'm just looking at the last quarter like we were doing around INR 4 crores. If I just subtract the Europe sale -- the Evoxx sales from the Europe sales, so besides the Evoxx, we've pretty much not done anything in this quarter. So could you comment on what happened? Like, why we've lost sales over there, in Europe?
Answer, mukund kabra
Mukund Kabra So Shreyans, I think quarterly comparison, as we have already been mentioning, it is not possible in our case. Page 8 of 23 Vasant Rathi People don't buy quarter-to-quarter and month-to-month.
Answer, beni rauka
Beni Rauka Yeah, it all depends on customers, their own procurement schedules.
Question
Shreyans Gathani Okay. I will take that offline. That's okay. Thank you. That's all from my end. Vasant Rathi: Thank you.
Answer, vasant rathi
Vasant Rathi Well, tariff is the tariff, 18%, 25% or 50%. Do you think anybody is willing to pay you 50% higher prices in the retail marketplace? Today, it's impossible. You will lose lot of -- entire sale or your entire sales. So it’s various strategies which we had to do, so that we don't lose customers, at the same time impact on the margins are not heavily affected. So, most of the things if you will see, that U.S. companies will pass on some of the cost increases to the customers during this 2026. There is a competition also which you have to keep in mind, whether competitors are ready to increase the prices or not.
Answer, vasant rathi
And you have to be competitive in the marketplace where others -- what others are doing. So, there are several factors that comes into picture. This is something -- the only thing it makes sense right now is yesterday's news will help us a little bit better in sense of how to normalize and be reasonable. So, we need to keep the customers comfortable. Rohan There is a point about that, yes, but people what last see for us actually. If you look at our numbers for FY25, those are also weak. And now after that, FY26, as you said, tariff is understandable.
Answer, vasant rathi
But, I mean, going forward, after the fact that the tariff has come down to 18% now. How do you see U.S. as a market going ahead for us?
Answer, vasant rathi
Vasant Rathi Yeah that, it will not have much of a difference for the market sales. We will see how the market is going -- overall market is taking the tariff, whether it is 15%, 20%, 18%. They will reflect in the marketplace and overall economy of the U.S. So if the U.S. economy remains strong with the employment, market will be good, and we see reasonably it should grow. Rohan Okay. And do you think any efforts are needed with respect to setting up a local base or getting person nel -- sales and marketing personnel there to further push for better growth there?
Answer, vasant rathi
Vasant Rathi We always are looking for a better growth, right. We always do our best. Page 10 of 23 Rohan It is not reflecting in the numbers hence, the little bit of pushback on that, sir.
Answer, vasant rathi
Vasant Rathi Sorry? Rohan It has not been really reflecting in the numbers, and hence, as investor s, I think there was slight bit of pushback on this matter.
Answer, vasant rathi
Vasant Rathi No. I understand. Rohan In future, I think, going ahead things will be better as you actually said.
Answer, vasant rathi
Vasant Rathi Yeah. No, no. We see a much better outlook. I mean, what we are looking at is a lot more inquiries, lot more interest that will reflect in next years. Rohan Okay. Because sir, I mean, given U.S. has such a large impact on our margins, if sales from there were to go down as they have been in the past, it would again affect the margins going ahead. So, I think given all of this, it holds a pretty much high importance, especially this large market for us.
Question
Abhishek Navalgund Yeah. Hi. Thanks for the opportunity. A couple of questions from my side. First, on the upcoming R&D Center, that is supposed to come in Nashik, I think, somewhere during this particular year. Is it possible to share, I mean, what area you will be targeting Page 11 of 23 to begin with? Because it was mentioned that it will be a far bigger setup as compared to what we have right now. So, any particular area and where you'll see the benefits coming in, maybe not immediately, but over the next couple of years from that perspective?
Answer, mukund kabra
Mukund Kabra So, Abhishek Ji, to begin with, we'll be targeting mostly on the strain development, protein engineering and on the fermentation side. That will be the first phase.
Question
Abhishek Navalgund Sure. But, I mean, the reason why I'm asking this question is, we have Serratiopeptidase as our largest product, but you get this question a lot, that which product can become like a next Serratiopeptidase for us. So, something similar can happen out of this R&D effort that you are intending to do?
Answer, mukund kabra
Mukund Kabra Yes, Abhishek Ji. We are working to do on -- there are many other products which we are working out there. And probably, the space will fasten up once this becomes live.
Question
Abhishek Navalgund Okay. And this will be largely targeted again for the exports only, right, abroad? I'm sorry, the timing of this commissioning of this facility is when? Sorry, I missed out on that part.
Answer, mukund kabra
Mukund Kabra Somewhere around the end of the second quarter of this coming year.
Question
Abhishek Navalgund End of second quarter, perfect. And next question on CapEx. I mean, we have maintained the capacity utilization at around 55%, 60%. I'm sure that considering since we have not done a large CapEx over the last few years, I mean, the CapEx, the capacity utilization must have been stopped. Any plans of CapEx being greenfield or brownfield expansion in the next one or two years?
Answer, mukund kabra
Mukund Kabra As we all always mention, whenever we feel like it will be necessary, we'll do it. Of course, the cost will be very low. Maybe, I guess, in the FY28-29, probably. Sorry, FY26-27, FY27-28 -- yeah, FY28-29 mostly and the cost will be about INR 50 crore at that point.
Question
And the Serratiopeptidase capacity, because this quarter was maybe kind of muted, but in nine months, the growth has been very strong. So, how are we placed in terms of capacity utilization for Serratiopeptidase? So, the JC Biotech plus our capacity is sufficient for, let's say, a couple of more years or?
Answer, mukund kabra
Mukund Kabra I think, our capacities are good enough as of now. We are well placed.
Question
Ketan Chheda Hi. Thank you for the opportunity. My query is with respect to the EU region. You know, in the last few years, if I take from 2021 onwards, we've had approvals wherein initially we had some four product approvals and now we are standing at nine product approvals for the EU region. But in these years from ‘21 to ‘25, our revenue has not increased significantly. It's about INR 32 crores to INR 33 crores in that zone. So could you tell us like what are we selling essentially in European Union, and why in spite of having so many product approvals our revenues are not growing in that region?
Answer, mukund kabra
Mukund Kabra So, our original target is the food segment in the European region, and that is what we are doing it. If you ask me, if you don't have these regulations, clearly our sales would have been zero, because you can't sell without this product being registered. So assuming that since it gets registered, you will have a significant revenue, it's not true. We are doing our best. We are trying to expand the market wherever it is possible. And I guess, we are still growing. This year also we grew into the European area.
Answer, mukund kabra
It's not like what de-grew or something of that.
Question
Ketan Chheda No. Sorry. I mean, I was referring to from -- I mentioned that 2021 till 2025, not just this nine months or last one year or so. I was talking about the last four odd years, four, five years. Because if you see the like, 32, we had it.
Answer, beni rauka
Beni Rauka So, I think in Europe, we have seen slightly the business model of our European company. So, they were having some contract research, external contract research, then internal for us, and then some product sale. So because of that realignment also, I think now the product sale was slightly down in couple of years. And now we are looking into that aspect and seeing that some kind of revenue we are going to get from that product sale business as well, which has been developed in India and then European company will take care of that. So that process is on, yes. And slightly -- the numbers that you rightly said is the kind of you know, is out of range bound so far. Page 13 of 23 Ketan Chheda Okay.
Question
I appreciate that response. The other question that I have is, I believe the one novel ingredient application that we have in Europe is again related to Serratiopeptidase. Now, once we have that approval, and assuming that probably it takes maybe a couple of years for us to kind of ramp up the sale of this novel ingredient in the European region. Is it likely that this product will continue to be the top revenue generator for us?
Answer, vasant rathi
Vasant Rathi Listen. If you know very well, you're aware, most of the issues, healthcare issues are inflammatory related, right. And we have to make sure that awareness is there. People find that these products are working very well for them, and it's a marketing effort, product establishment, brand establishment, etc. But we're sure that it will grow.
Question
Ravi Purohit Yeah. Hi. Thanks for taking my question. So, a couple of things. One is I think, over the last few years there has been a lot of discussion on U.S. business and your business. But outside of these two, the other geographies have actually done relatively better, and we see sustained growth from these geographies. So, can you just spend some time and help us understand what are the areas which are helping us with this growth and also whether these are sustainable numbers and whether we can build upon this over a period of time. So, if you would just share some insights on this, that was question number one. And second question was, we had created a 100% loan subsidiary to transfer
Answer, mukund kabra
Mukund Kabra So, when we talk about it, like we did a lot of registration in Asia and other countries. And if you really look into the rest of the world and Asia, those are the two markets which are giving us some results. The work which we did in the last two, three, fou r years, they are yielding some results right now, and we can see that there is certain growth in the Asia, as well as in the rest of the world area. Coming to your next question on the Nutrazyme we did like separate this entirety, and now the team is there, which is a focused team, which is working onto this area particularly. As of now, with the way we see it, this year it will be a small sale from around INR 1 crore to INR 1.5 crore for the end of the year. But we are constantly focusing on that. The team is young and dynamic, and we'll see the results in coming two to three years.
Question
And historically -- Mukund Kabra You may visit its website. If you want to, we do have somewhere around a basket of 10 to 12 products out there, and you can look at those products at the Wellfa.
Answer, vasant rathi
Vasant Rathi Yes, we have a brand, Wellfa brand. You can go and take a look at it and not only take a look at the brand. I suggest you buy some and try it yourself.
Question
Ravi Purohit Yes. We'll do most certainly, sir. And I think you had mentioned in the past that we historically have been a B2B company and not necessarily B2C company. So any idea, just because B2C is a very different animal altogether, right, in terms of marketing, ad spend, and getting -- so is there any, like, plan to kind of do some JV with some other company or do it ourselves or, because if the products are there and if they are good and they are doing it for other people for white labeling point of view, there could be an opportunity for us to kind of scale that business.
Answer, vasant rathi
Vasant Rathi Thank you for suggesting and confirming what we think in the same manner. So, both of them are thinking alike on that matter. We will do all of that, whatever you said, is grow our brands, align with few others, we have to see company people, and integrate and expand. That is a totally different biz than B2B. So, we have to think in a different way, and we will take all the expertise necessary in that particular market. That's why we are separating the company under Nutrazyme.
Question
Ravi Purohit Okay. And sir, in the past we have kind of briefly touched upon industrial enzymes. But if you could, kind of spare some time and help us understand, in the sense, what areas in industrial enzymes do we actually do or we intend to kind of add to our portfolio? Because that seems to be a very interesting space where given all the investments that are happening in India, either from green ammonia point of view or rare earth minerals point of view or a, well, whole variety of other things that are getting manufactured. And each time we kind of read some literature, what we come across is there are a lot of industrial enzymes which get used. So, is there anything that we do in any o
Answer, vasant rathi
Vasant Rathi Yeah. We are intended to get into those spaces on the growing marketplace. Our new R&D Center will really help us into that, because ultimately in all industrial segment, there is a performance which really counts right then and there. So, they don't wait. There are two areas which we have to show immediately of our performance and cost effectiveness, and it requires lot of work and proving that our enzymes are better than what they are using or not using at this point in time.
Question
Umang Shah Hi, sir. Thank you for taking my questions again. Sir, since Vasant Ji is also on the call, I just wanted to hear from him in terms of over the next two to three years, in which areas of enzymes that we see the most opportunity and will Advanced Enzymes be able to take part in it?
Answer, vasant rathi
Vasant Rathi Umang, thank you for calling. See, we had to stick with lot of these areas which we are already servicing, but we will also expand it to few other market areas. In the same market see, there are two, geographical marketplace and different application marketplace, and still our healthcare will be always a top area for us. But we are also going into biochemical processing and various other areas where the margins are not necessarily very high, but at the same time opportunities are enormous. So we are looking at both, different areas where we can expand and utilize our capacities very efficiently, at the same time grow our marketplace, and that's where the whole concentration of the management is at this time.
Question
Umang Shah Great, sir. Thank you so much. And sir, now in the budget buybacks have become better in terms of the tax implications. So would really suggest if, now where the stock price are, if you can consider a buyback of equity shares, that also helps in increasing the promoter holding and also helps long term shareholders increase the stake without any friction. So just if that's something you could consider. And the last thing was, if I heard it right, there was a loss in JC Biotech. Is that the right understanding?
Answer, mukund kabra
Mukund Kabra This quarter, yes. But you don't look at it Q-o-Q. Umang Shah Okay.
Question
Was there an operational loss or a one-time loss? Because it was EBITDA margin positive, but -- Page 16 of 23 Mukund Kabra There was some major, what you can call it, like a repair -- not repair.
Answer, mukund kabra
Stores and spare consumption for this quarter, which comes annually sometimes.
Question
Umang Shah Okay. Is it one-time, or does it happen once every year?
Answer, mukund kabra
Mukund Kabra Once in a year or twice in a year -- in two years once or that kind of thing. And this quarter, like again, there was some lower sale. But again, we don't get it Q-o-Q. Umang Shah Okay, great.
Question
Shubham Sehgal Yeah. I just had one question. So, in the earlier response, you mentioned that going forward you're seeing a much better outlook and a lot more inquiries on interest. Could you specify in which segment are we seeing all of these inquiries coming in?
Answer, vasant rathi
Vasant Rathi We are only in the two places, no, enzymes and probiotics. So, most of it is -- for example, our marketplace is a very different and dynamic marketplace. You know, in U.S. -- you are talking about U.S. market, right?
Question
Rohit Ohri Okay, Kabra ji. That makes a lot of sense. Thank you for answering my question. Thanks a lot.
Answer, vasant rathi
Vasant Rathi Well, as we said before also same thing. I don't think we are changing our tune anywhere. We'll grow 13 % to 15% double digit, more than double digit growth overall on a continuous basis in three to five years. There are a lot of hurdles will come in t he places, and there will be some sellings. But overall, we're very comfortable with our thinking, and accordingl y sometimes we can hit a very big way. The growth may increase rapidly, but overall we are 13% to 15% is very comfortable for us. Rohan That's good, sir.
Answer, beni rauka
Beni Rauka So almost nine months is gone. So I think another three months we have to see the impact, but it is most likely instead of 2% on EBITDA, I think it will be around 1% or so.
Questions about this call
- When was the Advanced Enzyme Technologies Q3 FY26 earnings call transcript filed?
- Advanced Enzyme Technologies filed the transcript with the exchange on 7 Feb 2026. This page is built from that transcript.
- What does this page list?
- 11 statements from the transcript across 5 topics, 5 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 30 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.